Hamilton S R
Department of Pathology and Oncology Center, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205.
J Cell Biochem Suppl. 1992;16G:41-6. doi: 10.1002/jcb.240501108.
Most adenocarcinomas of the colorectum arise in a visible benign precursor lesion, the adenoma, which is a monoclonal proliferation of dysplastic nonmalignant epithelial cells. The resultant adenoma-adenocarcinoma sequence represents the predominant pathogenetic pathway, in contrast to de novo carcinoma. Therefore, the adenoma is a tempting endpoint for chemoprevention trials. The adenoma-adenocarcinoma sequence occurs in diverse clinical settings. In familial adenomatous polyposis (FAP) syndrome, autosomal dominant inheritance of the mutated APC (adenomatous polyposis coli) gene on chromosome 5q21 typically results in thousands of adenomas in the colorectum and in lesser numbers in the proximal small bowel. Adenocarcinoma usually develops in only a few of these adenomas, typically in the left colon and duodenum. In hereditary nonpolyposis colorectal cancer (HNPCC) syndrome, autosomal dominant inheritance of an unidentified gene appears to result in small numbers of adenomas which progress frequently to adenocarcinoma, predominantly in the right or transverse colon. In familial aggregation of colorectal cancer without a recognizable syndrome, cancer and/or adenomas occur in pedigree members. In "sporadic" cancers and adenomas, family history is absent and the tumors are mainly in the left colon. Colorectal adenomas have variable characteristics including size, shape (polypoid vs. flat), villous architecture, and dysplasia. A variety of oncogenes and tumor suppressor genes are altered during progression. Epigenetic factors are important as evidenced by the disappearance of adenomas in FAP patients after ileorectal anastomosis or treatment with the nonsteroidal antiinflammatory drug sulindac. Several variations on the theme of the adenoma-carcinoma sequence are evident. Identification of the inherited and acquired genetic alterations as well as the interacting environmental factors will provide a rational basis for chemoprevention.(ABSTRACT TRUNCATED AT 250 WORDS)
大多数结直肠癌腺癌起源于一种可见的良性前驱病变——腺瘤,腺瘤是发育异常的非恶性上皮细胞的单克隆增殖。由此产生的腺瘤-腺癌序列代表了主要的致病途径,与新发癌形成对比。因此,腺瘤是化学预防试验诱人的终点。腺瘤-腺癌序列发生在多种临床情况下。在家族性腺瘤性息肉病(FAP)综合征中,5号染色体q21上突变的APC(腺瘤性息肉病 coli)基因的常染色体显性遗传通常导致结肠直肠中出现数千个腺瘤,近端小肠中数量较少。腺癌通常仅在这些腺瘤中的少数几个中发生,通常在左结肠和十二指肠。在遗传性非息肉病性结直肠癌(HNPCC)综合征中,一个未确定基因的常染色体显性遗传似乎导致少数腺瘤频繁进展为腺癌,主要发生在右半结肠或横结肠。在无明显综合征的结直肠癌家族聚集情况中,家系成员中会出现癌症和/或腺瘤。在“散发性”癌症和腺瘤中,没有家族病史,肿瘤主要位于左结肠。结直肠腺瘤具有多种特征,包括大小、形状(息肉状与扁平状)、绒毛结构和发育异常。在进展过程中,多种癌基因和肿瘤抑制基因会发生改变。表观遗传因素很重要,FAP患者在回肠直肠吻合术后或使用非甾体抗炎药舒林酸治疗后腺瘤消失就证明了这一点。腺瘤-癌序列主题存在多种变体。识别遗传和获得性基因改变以及相互作用的环境因素将为化学预防提供合理依据。(摘要截短于250字)